Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Ipsen obtains exclusive options to Spherical Nucleic Acids (SNAs™) currently under discovery evaluation for Huntington’s disease and Angelman syndrome Exicure will be responsible for discovery and certain pre-clinical development activities. In the event Ipsen exerci...
Ipsen S.A. (IPSEY) Q2 2021 Earnings Conference Call July 29, 2021 08:30 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - EVP and Group CFO Conference Call Participants Elizabeth Walton - Credit Suisse Sachin Jain, Bank - America Delphine Le Louet - Societe Generale Rosie Tur...
The following slide deck was published by Ipsen S.A. in conjunction with their 2021 Q1 earnings call. For further details see: Ipsen S.A. 2021 Q1 - Results - Earnings Call Presentation
Ipsen S.A. (IPSEY): 1H Non-GAAP EPS of €4.31; GAAP EPS of -€3.64.Revenue of €1.35B (+6.5% Y/Y)Press Release For further details see: Ipsen S.A. reports 1H results
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today announced its financial results for the first half of 2021: Strong financial results Total sales growth in H1 2021 of 11.0% at CER 1 , or 6.5% as reported...
koto_feja/E+ via Getty Images Ipsen ([[IPSEY]]) and BAKX Therapeutics have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture and commercialize BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors. Under the agreement, Ipsen will p...
Ipsen obtains an exclusive license to research, develop, manufacture and commercialize novel therapeutics targeted to the BCL-2 associated protein (BAX), an effector of apoptosis Investigational BKX-001 is an oral small-molecule activator of BAX, developed as a potential treatment...
Ipsen obtains the exclusive worldwide rights to develop and commercialize the investigational treatment mesdopetam which is based on a novel mechanism of action Mesdopetam, an oral dopamine D3-receptor antagonist, has completed Phase Ib and IIa clinical programs which showed p...
Shares of Exelixis (NASDAQ: EXEL) , an oncology-focused biopharmaceutical company, started sliding Monday in response to a disappointing clinical trial readout. Investors responding to results that weren't quite good enough have shaved 20.1% from the stock's price as of 11:30 a.m. E...
Sohel_Parvez_Haque/iStock via Getty Images Exelixis, (EXEL) down 6% premarket and Ipsen (IPSEY) announce that Phase 3 COSMIC-312 trial evaluating cabozantinib (Cabometyx) in combination with Roche's (RHHBY) atezolizumab vs. sorafenib in patients with previously untreated advanced he...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...